Matches in Nanopublications for { ?s ?p "[A subset of the cancer cell lines with a range of responses to TRAIL was selected from the panel for treatment with TRAIL combined with the PI3 Kinase/mTOR inhibitor PI-103 or the HSP90 inhibitor 17-AAG (tanespimycin).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP469376.RAeXnpJGzyQXk7T8VxoAtmBqGhOK9OqTtClIan6ul7PG8130_assertion description "[A subset of the cancer cell lines with a range of responses to TRAIL was selected from the panel for treatment with TRAIL combined with the PI3 Kinase/mTOR inhibitor PI-103 or the HSP90 inhibitor 17-AAG (tanespimycin).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP469376.RAeXnpJGzyQXk7T8VxoAtmBqGhOK9OqTtClIan6ul7PG8130_provenance.
- NP566982.RAvhHNOwPQ6Y1x5eDfF75hvV-AiSVc0FSusnhpsMPE6a0130_assertion description "[A subset of the cancer cell lines with a range of responses to TRAIL was selected from the panel for treatment with TRAIL combined with the PI3 Kinase/mTOR inhibitor PI-103 or the HSP90 inhibitor 17-AAG (tanespimycin).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP566982.RAvhHNOwPQ6Y1x5eDfF75hvV-AiSVc0FSusnhpsMPE6a0130_provenance.
- NP804321.RAmcGsXdNRar0RPk5UIeWOHOu8H8aHcQY395xwkbvvvgY130_assertion description "[A subset of the cancer cell lines with a range of responses to TRAIL was selected from the panel for treatment with TRAIL combined with the PI3 Kinase/mTOR inhibitor PI-103 or the HSP90 inhibitor 17-AAG (tanespimycin).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP804321.RAmcGsXdNRar0RPk5UIeWOHOu8H8aHcQY395xwkbvvvgY130_provenance.
- NP567117.RA-GhxnDhEW5FJKz5dJhSo-OppNdp3rQqcLEJck-_dYNU130_assertion description "[A subset of the cancer cell lines with a range of responses to TRAIL was selected from the panel for treatment with TRAIL combined with the PI3 Kinase/mTOR inhibitor PI-103 or the HSP90 inhibitor 17-AAG (tanespimycin).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP567117.RA-GhxnDhEW5FJKz5dJhSo-OppNdp3rQqcLEJck-_dYNU130_provenance.
- NP468988.RAPfE81BJAgJUY8fzsgTOsNUnP8qDGT7AOOXwuDEmlBTE130_assertion description "[A subset of the cancer cell lines with a range of responses to TRAIL was selected from the panel for treatment with TRAIL combined with the PI3 Kinase/mTOR inhibitor PI-103 or the HSP90 inhibitor 17-AAG (tanespimycin).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP468988.RAPfE81BJAgJUY8fzsgTOsNUnP8qDGT7AOOXwuDEmlBTE130_provenance.
- NP803720.RA5goIEUXKxnRrf8qpHVorI5dtTTuU30F-hCoauIUxnEw130_assertion description "[A subset of the cancer cell lines with a range of responses to TRAIL was selected from the panel for treatment with TRAIL combined with the PI3 Kinase/mTOR inhibitor PI-103 or the HSP90 inhibitor 17-AAG (tanespimycin).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP803720.RA5goIEUXKxnRrf8qpHVorI5dtTTuU30F-hCoauIUxnEw130_provenance.